Q-omics provides the consensus-scored KIAA1217 profile across patient tissues and cancer cell-line models. KIAA1217 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KIAA1217 is differentially expressed in 11, with the highest sampling consensus in UCEC. Additionally, KIAA1217 RNA expression shows 19,337 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, UCEC, and KIRP as cancer lineages where KIAA1217 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA1217 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA1217 survival associations across molecular data types. KIAA1217 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (12) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA1217 RNA expression–survival associations across cancer types. High KIAA1217 expression shows unfavorable associations in LIHC and BLCA, but favorable associations in UVM, KIRC, HNSC and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KIAA1217 RNA expression.
This table summarizes KIAA1217 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KIAA1217. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA1217 shows lower tumor expression in KICH and KIRC and higher tumor expression in UCEC, LUSC, STAD and LUAD. The UCEC box plot shows higher KIAA1217 RNA expression in tumor versus normal tissue (log2 FC = +1.146, t-test p = .002).
This table shows molecular features associated with KIAA1217 in patient tissues and cancer cell lines. In patient samples, KIAA1217 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA1217 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
